📈 BFBIO: BUY Signal (8/10) – Corporate Briefing Session – Presentation

📌 Key Takeaways

• ✅ BFBIO’s revenue for FY2025 reached PKR 5,837 million, a 60% increase year-over-year.
• 📈 Net profit for FY2025 increased by 16% year-over-year to PKR 447 million.
• 📊 Gross margin for FY2025 stood at 39%.
• 💰 EBITDA margin for FY2025 was 18%.
• 💸 Net profit margin for FY2025 was 8%.
• 🚀 Revenue for the first quarter of FY2026 soared to PKR 2,432 million, a 75% year-over-year increase.
• 💰 Net profit for the first quarter of FY2026 rose by 38% year-over-year to PKR 160 million.
• 📊 Gross margin for the first quarter of FY2026 was 43%.
• 💰 EBITDA margin for the first quarter of FY2026 stood at 15%.
• 💸 Net profit margin for the first quarter of FY2026 was 7%.
• 🏭 Commissioning of Line II suggests increased production capacity.
• 💊 Recent product launches, including Ferulin and Zeptide, indicate innovation and market expansion.
• 🇵🇰 Pakistan’s retail pharma market is valued at Rs. 1.12 Trillion.
• ⬆️ The pharma market has seen a 17.28% growth over the last year and a 17.54% CAGR over the last 5 years.

🎯 Investment Thesis

BFBIO represents a compelling investment opportunity due to its strong growth trajectory and innovative product portfolio. The expansion of manufacturing capacity and recent product launches position the company for continued success. A BUY recommendation is warranted with a price target based on a DCF valuation, assuming continued growth at a slightly moderated rate. The time horizon is MEDIUM_TERM, anticipating that the market will recognize the company’s potential within the next 2-3 years.